Article
Medicine, Research & Experimental
Carolyn Rydyznski Moderbacher, Christina Kim, Jose Mateus, Joyce Plested, Mingzhu Zhu, Shane Cloney-Clark, Daniela Weiskopf, Alessandro Sette, Louis Fries, Gregory Glenn, Shane Crotty
Summary: NVX-CoV2373 vaccine induces CD4(+) and CD8+ T cell responses, and the production of CD4(+) T cells is correlated with the generation of neutralizing antibodies. This suggests that robust CD4(+) T cell generation may be a key characteristic of NVX-CoV2373 in supporting humoral immune responses.
JOURNAL OF CLINICAL INVESTIGATION
(2022)
Article
Medicine, General & Internal
Paul T. Heath, Eva P. Galiza, David N. Baxter, Marta Boffito, Duncan Browne, Fiona Burns, David R. Chadwick, Rebecca Clark, Catherine Cosgrove, James Galloway, Anna L. Goodman, Amardeep Heer, Andrew Higham, Shalini Iyengar, Arham Jamal, Christopher Jeanes, Philip A. Kalra, Christina Kyriakidou, Daniel F. McAuley, Agnieszka Meyrick, Angela M. Minassian, Jane Minton, Patrick Moore, Imrozia Munsoor, Helen Nicholls, Orod Osanlou, Jonathan Packham, Carol H. Pretswell, Alberto San Francisco Ramos, Dinesh Saralaya, Ray P. Sheridan, Richard Smith, Roy L. Soiza, Pauline A. Swift, Emma C. Thomson, Jeremy Turner, Marianne E. Viljoen, Gary Albert, Iksung Cho, Filip Dubovsky, Greg Glenn, Joy Rivers, Andreana Robertson, Kathy Smith, Seth Toback
Summary: The NVX-CoV2373 vaccine demonstrated an efficacy of 89.7% in a phase 3 trial with over 15,000 participants, with mild and transient reactogenicity. It showed high efficacy against the B.1.1.7 variant and a low incidence of adverse events.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Review
Medicine, General & Internal
Dan H. Barouch
Summary: This article reviews the protective effects of vaccination and prior infection on severe Covid-19, and proposes future research directions.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Multidisciplinary Sciences
Jing-Hui Tian, Nita Patel, Robert Haupt, Haixia Zhou, Stuart Weston, Holly Hammond, James Logue, Alyse D. Portnoff, James Norton, Mimi Guebre-Xabier, Bin Zhou, Kelsey Jacobson, Sonia Maciejewski, Rafia Khatoon, Malgorzata Wisniewska, Will Moffitt, Stefanie Kluepfel-Stahl, Betty Ekechukwu, James Papin, Sarathi Boddapati, C. Jason Wong, Pedro A. Piedra, Matthew B. Frieman, Michael J. Massare, Louis Fries, Karin Lovgren Bengtsson, Linda Stertman, Larry Ellingsworth, Gregory Glenn, Gale Smith
Summary: The study reports the development of a SARS-CoV-2 subunit vaccine candidate that contains full-length spike protein stabilized in its prefusion conformation, showing immunogenicity in mice and protection in baboons with Matrix-M adjuvanted vaccine, supporting ongoing phase 1/2 clinical evaluation of NVX-CoV2373 with Matrix-M (NCT04368988).
NATURE COMMUNICATIONS
(2021)
Article
Medicine, General & Internal
V. Shinde, S. Bhikha, Z. Hoosain, M. Archary, Q. Bhorat, L. Fairlie, U. Lalloo, M. S. L. Masilela, D. Moodley, S. Hanley, L. Fouche, C. Louw, M. Tameris, N. Singh, A. Goga, K. Dheda, C. Grobbelaar, G. Kruger, N. Carrim-Ganey, V. Baillie, T. de Oliveira, A. Lombard Koen, J. J. Lombaard, R. Mngqibisa, A. E. Bhorat, G. Benade, N. Lalloo, A. Pitsi, P. -L. Vollgraaff, A. Luabeya, A. Esmail, F. G. Petrick, A. Oommen-Jose, S. Foulkes, K. Ahmed, A. Thombrayil, L. Fries, S. Cloney-Clark, M. Zhu, C. Bennett, G. Albert, E. Faust, J. S. Plested, A. Robertson, S. Neal, I. Cho, G. M. Glenn, F. Dubovsky, S. A. Madhi
Summary: The NVX-CoV2373 vaccine showed efficacy in preventing Covid-19, with higher vaccine efficacy observed among HIV-negative participants. Most infections were caused by the B.1.351 variant.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Review
Multidisciplinary Sciences
Daniel M. Altmann, Rosemary J. Boyton
Summary: A diverse range of first-generation SARS-CoV-2 vaccines have been successful in controlling the COVID-19 pandemic, although inequitable distribution remains an issue. Future challenges include optimizing immunological boosting strategies and building an immune repertoire that can protect against upcoming viral variants.
Article
Biochemistry & Molecular Biology
Zeli Zhang, Jose Mateus, Camila H. Coelho, Jennifer M. Dan, Carolyn Rydyznski Moderbacher, Rosa Isela Galvez, Fernanda H. Cortes, Alba Grifoni, Alison Tarke, James Chang, E. Alexandar Escarrega, Christina Kim, Benjamin Goodwin, Nathaniel Bloom, April Frazier, Daniela Weiskopf, Alessandro Sette, Shane Crotty
Summary: Multiple COVID-19 vaccines have successfully protected against symptomatic cases and deaths. Comparisons of T cell, B cell, and antibody responses to different vaccines can provide insights into protective immunity against COVID-19, particularly immune memory. mRNA vaccines and Ad26.COV2.S induced strong T cell responses, while mRNA vaccines showed substantial declines in antibodies.
Article
Immunology
Katherine Smith, Karim Hegazy, Miranda R. Cai, Irene McKnight, Matthew D. Rousculp, Katia Alves
Summary: This article summarizes the safety of the NVX-CoV2373 primary series in adults, showing that it has an acceptable safety profile with mostly mild-to-moderate reactions. Serious adverse events and deaths occurred at a similar rate in the NVX-CoV2373 and placebo groups.
Article
Oncology
Astha Thakkar, Jesus D. Gonzalez-Lugo, Niyati Goradia, Radhika Gali, Lauren C. Shapiro, Kith Pradhan, Shafia Rahman, So Yeon Kim, Brian Ko, R. Alejandro Sica, Noah Kornblum, Lizamarie Bachier-Rodriguez, Margaret McCort, Sanjay Goel, Roman Perez-Soler, Stuart Packer, Joseph Sparano, Benjamin Gartrell, Della Makower, Yitz D. Goldstein, Lucia Wolgast, Amit Verma, Balazs Halmos
Summary: Most cancer patients show high seroconversion rates after receiving COVID-19 vaccines, but those with hematologic malignancies, especially after highly immunosuppressive therapies, exhibit lower conversion rates. Patients on immune checkpoint inhibitor therapy or hormonal therapy display high conversion rates.
Article
Cardiac & Cardiovascular Systems
Manuela De Michele, Joshua Kahan, Irene Berto, Oscar G. Schiavo, Marta Iacobucci, Danilo Toni, Alexander E. Merkler
Summary: The risk of stroke and cerebrovascular disease complicating SARS-CoV-2 infection has been extensively reported. The rapid development and mass vaccination of DNA and mRNA vaccines against SARS-CoV-2 have led to rare but catastrophic cases of thrombosis. This review provides an overview of stroke and cerebrovascular complications of SARS-CoV-2 infection, as well as vaccinations, with a focus on vaccine-induced immune thrombotic thrombocytopenia. A therapeutic protocol is proposed based on available data.
CIRCULATION RESEARCH
(2022)
Article
Biochemistry & Molecular Biology
Martina Patone, Lahiru Handunnetthi, Defne Saatci, Jiafeng Pan, Srinivasa Vittal Katikireddi, Saif Razvi, David Hunt, Xue W. Mei, Sharon Dixon, Francesco Zaccardi, Kamlesh Khunti, Peter Watkinson, Carol A. C. Coupland, James Doidge, David A. Harrison, Rommel Ravanan, Aziz Sheikh, Chris Robertson, Julia Hippisley-Cox
Summary: Emerging reports of rare neurological complications associated with COVID-19 infection and vaccinations are leading to concerns in regulatory, clinical, and public health sectors. A self-controlled case series study in England showed an increased risk of rare neurological complications following COVID-19 vaccination and infection. The study highlighted a higher risk of Guillain-Barre syndrome after ChAdOx1nCoV-19 vaccination.
Review
Immunology
Zhou Zhou, Yimiao Zhu, Ming Chu
Summary: This article reviews the current status of mutations in SARS-CoV-2 variants, discusses the different approaches used in the development of COVID-19 vaccines, and explores the effectiveness of COVID-19 vaccines against SARS-CoV-2 variants.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Magdalena Mueller-Enz, Christina Woopen, Georges Katoul Al Rahbani, Rocco Haase, Marie Dunsche, Tjalf Ziemssen, Katja Akguen
Summary: This study aimed to determine whether the adjuvanted protein-based vaccine NVX-CoV2373 can induce an immune response to SARS-CoV-2 in multiple sclerosis patients with inadequate responses to prior mRNA/viral vector vaccination. The results showed that the protein-based vaccine was able to elicit a specific immune response to SARS-CoV-2 in patients with inadequate immune responses.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Medicine, General & Internal
Nickolas Lewis, Laura C. Chambers, Huong T. Chu, Taylor Fortnam, Roberta De Vito, Lisa M. Gargano, Philip A. Chan, James McDonald, Joseph W. Hogan
Summary: This study aimed to investigate the effect of vaccination after recovery from COVID-19 on preventing SARS-CoV-2 reinfection. The findings suggest that individuals who remained unvaccinated faced a relatively high risk of reinfection, while vaccination after recovery from COVID-19 was associated with reducing the risk of reinfection by approximately half.
Article
Immunology
Yufei Wu, Huanjie Li, Yangyang Wang, Ping Huang, Yihui Xu, Mingjie Xu, Qianqian Zhao, Yunying Zhou, Jun Wang, Mingyu Ji, Yunshan Wang
Summary: As the third year of the COVID-19 pandemic continues, vaccination remains the most effective way to prevent infection and symptomatic illness. This study analyzed the current state of COVID-19 vaccination and the necessity of booster vaccinations. By studying antibody levels and immune indicators, it was determined that a third dose of the COVID-19 vaccine is necessary to maintain protective effects.